8-K - MAIA Biotechnology, Inc. (0001878313) (Filer)

DEFA14A - MAIA Biotechnology, Inc. (0001878313) (Filer)

SCHEDULE 13G - MAIA Biotechnology, Inc. (0001878313) (Subject)

8-K - MAIA Biotechnology, Inc. (0001878313) (Filer)

424B5 - MAIA Biotechnology, Inc. (0001878313) (Filer)

10-Q - MAIA Biotechnology, Inc. (0001878313) (Filer)

DEFA14A - MAIA Biotechnology, Inc. (0001878313) (Filer)

8-K - MAIA Biotechnology, Inc. (0001878313) (Filer)

8-K - MAIA Biotechnology, Inc. (0001878313) (Filer)

S-8 - MAIA Biotechnology, Inc. (0001878313) (Filer)

4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

4/A - MAIA Biotechnology, Inc. (0001878313) (Issuer)

4/A - MAIA Biotechnology, Inc. (0001878313) (Issuer)

4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

MAIA's novel telomere-targeting therapy being evaluated as a third-line treatment for advanced non-small cell lung cancer CHICAGO, June 04, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today provided a patient enrollment update for its ongoing pivotal Phase 3 trial, THIO-104, evaluating its novel telomere-targeting therapy as a third-line (3L) treatment for advanced non-small cell lung cancer (NSCLC). To date, 29 patients have been dosed among 34 activated trial sites in 6 foreign countries. Vlad Vitoc, M.D., Founder and Chief Executive Officer o

Additional data from THIO-101 trial expansion studies may further support a potential Accelerated Approval filing with FDA FDA-cleared IND updates detail latest efficacy data and enriched manufacturing protocols CHICAGO, June 03, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared an amendment to update its investigational new drug (IND) application which enables MAIA to open U.S. enrollment for the expansion of the Phase 2 THIO-101 trial of its lead candidate, ateganosine, as

CHICAGO, June 02, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that its founder and CEO Vlad Vitoc, M.D. and Director Stan V. Smith, Ph.D. have increased their ownership positions through open market purchases. Approximately 72,700 shares of MAIA common stock were purchased by Dr. Vitoc on June 6, 2026, at an average common stock price of $1.3877. Approximately 75,000 shares of MAIA common stock were purchased by Dr. Smith on June 6, 2026, at an average common stock price of $1.336. "Our continuing investments underscore our stron

CHICAGO, June 01, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, delivered a poster presentation on May 31, 2026, featuring the methodology and study design for its pivotal Phase 3 clinical trial (THIO-104) at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO 2026), being held May 29 – June 2, 2026, in MAIA's home city of Chicago, Illinois. THIO-104 evaluates the efficacy of MAIA's telomere targeting agent, ateganosine, administered in sequence with a checkpoint inhibitor (CPI) in third-line non-small cell lung cancer (NSCLC)

New York, May 18, 2026 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an update note on MAIA Biotechnology, Inc. (NYSE:MAIA). The research summary below is from a report commissioned by MAIA Biotechnology, Inc. and produced by Diamond Equity Research. The update note includes detailed information on the MAIA Biotechnology's business, recent updates, management commentary, financial results, valuation, and risks. The full update note is available below. MAIA Biotechnology May 2026 Update Note Highlights from the note include:                                               Activates First U.S.

Exceptional measures of efficacy observed in THIO-101 Phase 2 trial to date include disease control, response rates, and survival data well above standard of care benchmarks 50,000 advanced NSCLC diagnoses in the U.S. annually CHICAGO, April 16, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that it has activated the first U.S. clinical site in its Phase 2 THIO-101 expansion trial of its lead investigational therapy as a third-line (3L) treatment for non-small cell lung cancer (NSCLC). "We are thrilled to activate the expansion of

Strong participation in recent $33 million common stock offering highlights investor confidence in late-stage clinical momentum and commercial potential Statistical assessments point to high probability of technical successin Phase 3 full approval trial FDA granted Fast Track designation for dual mechanism therapy as a treatment for non-small cell lung cancer (NSCLC) CHICAGO, April 08, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that net proceeds from its $33 million public offering of common stock in March 2026 are expected to

New York, March 27, 2026 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an update note on MAIA Biotechnology, Inc. (NYSE:MAIA). The research summary below is from a report commissioned by MAIA Biotechnology, Inc. and produced by Diamond Equity Research. The update note includes detailed information on the MAIA Biotechnology's business, recent updates, management commentary, financial results, valuation, and risks. The full update note is available below. MAIA Biotechnology March 2026 Update Note Highlights from the note include:                                               FY 2025 Financial

New York, March 05, 2026 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an update note on MAIA Biotechnology, Inc. (NYSE:MAIA). The research summary below is from a report commissioned by MAIA Biotechnology, Inc. and produced by Diamond Equity Research. The update note includes detailed information on the MAIA Biotechnology's business, recent updates, management commentary, financial results, valuation, and risks. The full update note is available below. MAIA Biotechnology March 2026 Update Note Highlights from the note include:                                               $30 Million Equit

Financing included participation by healthcare-dedicated investors alongsideexisting shareholders CHICAGO, IL, March 04, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the closing of its previously announced underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $1.50 per share for aggregate gross proceeds of $30 million, prior to deducting underwriting discounts and other offering expenses. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 3,000,0

Planning for Phase 2 clinical trial in hepatocellular carcinoma (HCC) underway MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced the appointment of two prominent oncologists to its Scientific Advisory Board (SAB), Claudia Fulgenzi, MD, and David J. Pinato, MD, MRCP (UK), PhD. Both are specialists in hepatocellular carcinoma (HCC), a tumor type to be studied in future clinical trials of MAIA's lead candidate ateganosine (THIO) sequenced with a checkpoint inhibitor. As SAB members they will advise MAIA on designs and protocols for its company sponsored trial (C

Poster highlights potential predictive biomarker for therapeutic response in advanced non-small cell lung cancer (NSCLC)   MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that an abstract detailing a potential predictive biomarker for THIO treatment was selected for poster presentation at the European Lung Cancer Congress 2025 (ELCC 2025) taking place, March 26-29, in Paris, France. ELCC is a program of the European Society for Medical Oncology (ESMO). "We are proud to join ELCC 2025, a premier conference focused directly on the science of thoracic oncology," said V

Acclaimed academic researcher has led 40+ multicenter phase 2 and phase 3 clinical studies MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the appointment of Professor Saadettin Kilickap, M.D. to its Scientific Advisory Board (SAB). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321173734/en/Professor Saadettin Kilickap, M.D., Scientific Advisor to MAIA Biotechnology (Photo: Business Wire) Dr. Kilickap is a professor at the Istinye University Faculty of Medicine, Department of Medical Oncology, Liv Hos

New Scientific Advisory Board member played instrumental role in FDA approval and commercialization of multiple blockbuster products CHICAGO, IL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the appointment of immuno-oncology leader Remus Vezan, M.D., Ph.D., to its Scientific Advisory Board (SAB). With over 20 years of academic and biopharmaceutical industry experience, Dr. Vezan is a highly regarded leader in drug development of novel therapeutic modalities, including cell and gene therapies, and played a pivotal role in the devel

SC 13D/A - MAIA Biotechnology, Inc. (0001878313) (Subject)

SC 13D - MAIA Biotechnology, Inc. (0001878313) (Subject)

SC 13D - MAIA Biotechnology, Inc. (0001878313) (Subject)

SC 13G - MAIA Biotechnology, Inc. (0001878313) (Subject)

SC 13G - MAIA Biotechnology, Inc. (0001878313) (Subject)

SC 13G - MAIA Biotechnology, Inc. (0001878313) (Subject)